Peter Voorhees, MD
Novel agents and treatment combinations have rapidly expanded the armamentarium in multiple myeloma. However, additional progress is needed to extend these successes to a greater population of patients, according to Peter Voorhees, MD.
on Hematologic Malignancies.
OncLive: What treatments are available for newly diagnosed patients with multiple myeloma?
I had the opportunity to talk about the treatment of newly diagnosed patients who are not necessarily eligible for autologous stem cell transplantation. There are 3 things in particular that are worth commenting on. First off, there has been a larger body of literature that has come forth supporting the paradigm of continuous treatment until disease progression. The FIRST trial is a good example of that. This was a randomized phase III study that has been published for a few years now, which compared continuous lenalidomide (Revlimid)/dexamethasone therapy versus 18 months of treatment. There was a clear improvement in PFS with [the continuous] approach.
... to read the full story